References
- Biary R, Kremer A, Goldfarb DS, et al. Falsely elevated salicylate concentration in a patient with hypertriglyceridemia. Toxicol Commun. 2018;2(1):1–2. DOI:10.1080/24734306.2017.1412566.
- You K, Bittikofer JA. Quantification of salicylate in serum by use of salicylate hydroxylase. Clin Chem. 1984;30(9):1549.
- Baer DM, Paulson RA. The effect of hyperlipidemia on therapeutic drug assays. Ther Drug Monit. 1987;9(1):72–77.
- Kroll MH. Evaluating interference caused by lipemia. Clin Chem. 2004;50(11):1968–1969. DOI:10.1373/clinchem.2004.038075.
- Meany D, Schowinsky J, Clarke W. Effects of hemolysis and lipemia on the COBAS salicylate and acetaminophen assays compared to GDS assays. Clin Biochem. 2008;41(18):1486–1488. doi: 10.1016/j.clinbiochem.2008.09.111.
- Kroll MH, Elin RJ. Interference with clinical laboratory analyses. Clin Chem. 1994;40(11 Pt 1):1996–2005.
- Charlton NP, Lawrence DT, Wallace KL. Falsely elevated salicylate levels. J Med Toxicol. 2008;4(4):310–311. PubMed PMID: 19031386; PubMed Central PMCID: PMCPMC3550119.